Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity

Maria Rovithi, Henk M.W. Verheul*

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)287-289
Number of pages3
JournalAngiogenesis
Volume20
Issue number3
DOIs
Publication statusPublished - 1 Aug 2017

Cite this